Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies

Clinical Lymphoma Myeloma & Leukemia(2020)10.1016/j.clml.2020.02.006Source: DataRank Database

A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2020). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 0.23)OA: greenTopics (94)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

JULIAN R. DAVIS ORCID,Brian A. Jonas ORCID,Joseph M. Tuscano ORCID,Aaron S. Rosenberg ORCID,Mehrdad Abedi ORCID

Live enrichment

PubMed:32171691 PMC:PMC8530379 OpenAlex:https://openalex.org/W3008575632

National Institutes of Health

Grant: 5K12-CA138464

NCI NIH HHS

Grant: P30 CA093373

NCI NIH HHS

Grant: K12 CA138464

National Institutes of Health

Grant: 5K12CA138464-10

Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis

AbbVie

Gilead Sciences

Celgene

Daiichi Sankyo Company

Genentech

Amgen

Novartis Pharmaceuticals Corporation

Takeda Pharmaceuticals U.S.A.

Bristol-Myers Squibb

National Cancer Institute

FWCI

0.23

Citation Percentile

0.5%

Citation Trend

2021

2023

2024

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8530379

publisherhttps://api.elsevier.com/content/article/PII:S2152265020300860?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265020300860?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clml.2020.02.006

Fields of Study

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research0301 basic medicine0302 clinical medicine03 medical and health sciences

MeSH Terms

EverolimusBendamustine HydrochlorideAdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansMaleMiddle AgedProspective StudiesHematologic NeoplasmsYoung Adult

Keywords

BendamustineMedicineLeukopeniaInternal medicineEverolimusNeutropeniaAdverse effectLymphomaGastroenterologyTolerabilityOncologyRituximabChemotherapyMultiple myelomaHodgkin LymphomaNon-hodgkin LymphomaMaleBendamustine Hydrochloride (mesh)Clinical Research (rcdc)Cardiovascular Medicine and Haematology1103 Clinical Sciences (for)80 and over80 and over (mesh)Bendamustine HydrochlorideLymphatic Research (rcdc)Prospective Studies32 Biomedical and Clinical Sciences (for-2020)Male (mesh)Hodgkin's DiseaseCancerCancer (rcdc)Aged, 80 and overHumans (mesh)Young Adult (mesh)Lymphoma (rcdc)3201 Cardiovascular medicine and haematology (for-2020)Hematology1112 Oncology and Carcinogenesis (for)Middle AgedHodgkin's Disease (rcdc)Antineoplastic Agents (mesh)6.1 PharmaceuticalsHematologic NeoplasmsFemalePatient SafetyAdultLymphatic ResearchHematologic Neoplasms (mesh)Oncology and CarcinogenesisClinical Trials and Supportive ActivitiesClinical SciencesClinical Trials and Supportive Activities (rcdc)610Antineoplastic AgentsRare Diseases (rcdc)Young AdultRare DiseasesClinical Research615Middle Aged (mesh)3211 Oncology and carcinogenesis (for-2020)HumansProspective Studies (mesh)AgedHematology (rcdc)6.1 Pharmaceuticals (hrcs-rac)Biomedical and Clinical SciencesPatient Safety (rcdc)Aged (mesh)Cancer (hrcs-hc)Everolimus (mesh)Orphan DrugFemale (mesh)Orphan Drug (rcdc)Adult (mesh)

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies

FAIR Checklist

Authors (6)

Funding (14 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)